-
Capital, M&A & Industry Strategy4 weeks agoBuilding again in rare diseases, Shionogi pays $2B for IntraBio
BIOCENTURY | DEALSBUILDING AGAIN IN RARE DISEASES, SHIONOGI PAYS $2B FOR INTRABIOAcquisition would give Japanese pharma a therapy approved for two disorders, including one first-in-disease indication
-
Clinical Trials & Development4 weeks agoVaxcyte’s Phase III data strengthen case for broader pneumococcal coverage
BIOCENTURY | PRODUCT DEVELOPMENTVAXCYTE’S PHASE III DATA STRENGTHEN CASE FOR BROADER PNEUMOCOCCAL COVERAGEBioCentury’s Clinical Report, Sept. 29 – Oct. 5
-
Synthetic Biology, Genomics & Advanced Therapeutics4 weeks agoNovartis turns to mRNA-encoded engagers for B cell depletion
BIOCENTURY | DEALSNOVARTIS TURNS TO MRNA-ENCODED ENGAGERS FOR B CELL DEPLETIONPharma pays $575M up front for Abogen’s CD3 x CD19 engager to treat autoimmune diseases
-
Drug Discovery & Therapeutics4 weeks agoCircle’s $92.5M round puts cyclin D1 program ahead of clinical lead
BIOCENTURY | PRODUCT DEVELOPMENTCIRCLE’S $92.5M ROUND PUTS CYCLIN D1 PROGRAM AHEAD OF CLINICAL LEADPreclinical combination data drive CID-165’s priority over CID-078, with deeper breast cancer responses...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoPharma partnering in China gets earlier and broader
BIOCENTURY | DATA BYTEPHARMA PARTNERING IN CHINA GETS EARLIER AND BROADERMerck, Novo and Novartis pay ≥$300M apiece for early assets as China partnering expands beyond cancer...
-
Capital, M&A & Industry Strategy4 weeks agoHatteras banks on portfolio with upsized Opportunity Fund
BIOCENTURY | FINANCEHATTERAS BANKS ON PORTFOLIO WITH UPSIZED OPPORTUNITY FUNDFirm sets $100M target for vehicle designed for further investment in private portfolio companies, even amid improved...
-
Capital, M&A & Industry Strategy4 weeks agoTrio of biotechs draw nine-figure fundings: Public Equity Report
BIOCENTURY | FINANCETRIO OF BIOTECHS DRAW NINE-FIGURE FUNDINGS: PUBLIC EQUITY REPORTImmix, Sagimet, and Pyxis all receive funding; plus AstraZeneca/Summit
-
Global Biotechnology & Pharmaceutical Markets1 month agoChina biopharma still faces a long road to globalization
BIOCENTURY | GUEST COMMENTARYCHINA BIOPHARMA STILL FACES A LONG ROAD TO GLOBALIZATIONChinese science is already flowing out of the Oktagon. Chinese companies are not. Can this...
-
Capital, M&A & Industry Strategy1 month agoHidden in plain sight: Canaan’s Grant on company building in white spaces
BIOCENTURY | FINANCEHIDDEN IN PLAIN SIGHT: CANAAN’S GRANT ON COMPANY BUILDING IN WHITE SPACESJulie Grant joins The BioCentury Show to discuss company building toward M&A, what...
-
Capital, M&A & Industry Strategy1 month agoKallyope becomes TriGemX, raises $94M for migraine therapy: Venture Report
BIOCENTURY | FINANCEKALLYOPE BECOMES TRIGEMX, RAISES $94M FOR MIGRAINE THERAPY: VENTURE REPORTPlus: At least four rounds for European biotechs; Link Cell’s series A extension; and more
Widespread atropine use fails to sway FDA advisors on Sydnexis data
At least 11 PDUFAs on FDA’s November docket
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
